Search
COPD Paid Clinical Trials in Indiana
A listing of 6 COPD clinical trials in Indiana actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 6 of 6
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
COPD
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
The state of Indiana currently has 6 active clinical trials seeking participants for COPD research studies. These trials are conducted in various cities, including Indianapolis, South Bend, Fort Wayne and Evansville.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
COPD Clinical Research Study
Recruiting
Living with COPD? We are transforming health by bringing clinical trials to you.
Don’t let financial stress hold you back. All pre-screening tests will be provided at no cost to you. See if you pre-qualify and if there is a location that is convenient for you.
Don’t let financial stress hold you back. All pre-screening tests will be provided at no cost to you. See if you pre-qualify and if there is a location that is convenient for you.
Conditions:
COPD
Chronic Obstructive Pulmonary Disease
Pulmonary Disease
Chronic Obstructive
Chronic Obstructive Pulmonary Disease (COPD)
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Recruiting
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
04/23/2025
Locations: Research Site, Valparaiso, Indiana
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
Recruiting
This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COPD) who are former or current smokers and have a history of frequent exacerbations.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
04/03/2025
Locations: ASHA Clinical Research - ClinEdge - PPDS, Hammond, Indiana
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
Recruiting
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
03/31/2025
Locations: Research Site, Evansville, Indiana +2 locations
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
Recruiting
Subjects who completed either OBERON or TITANIA will be offered the opportunity to consent for this Multicentre, Double-blind, Randomised, Placebo controlled, Parallel Group, Phase 3, extension study to evaluate the safety and efficacy of Tozorakimab in adult participants with symptomatic COPD.
Gender:
ALL
Ages:
Between 40 years and 130 years
Trial Updated:
03/14/2025
Locations: Research Site, Greenwood, Indiana
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
A Study to Evaluate Solrikitug in Participants With COPD (ZION)
Recruiting
A Randomized, Double-blind, Placebo-controlled, Multiple Dose-Ranging Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Solrikitug in Participants with Chronic Obstructive Pulmonary Disease (COPD).
Gender:
ALL
Ages:
Between 40 years and 75 years
Trial Updated:
02/20/2025
Locations: Research Site 022, Merrillville, Indiana
Conditions: COPD
Acoustic Waveform Respiratory Evaluation
Recruiting
The study will evaluate the feasibility of using smartphone speakers and microphones to evaluate the caliber of the airways, detect airway obstruction, aid in airway disease diagnosis, and identify disease exacerbations.
Gender:
ALL
Ages:
Between 8 years and 65 years
Trial Updated:
09/11/2024
Locations: Indiana University, Indianapolis, Indiana
Conditions: Asthma, COPD, Cystic Fibrosis, Ciliary Motility Disorders, Bronchiectasis, Airway Malacia, Healthy Control
1 - 6 of 6